BMO Capital Markets upgraded to Outperform from Market Perform and raised its price target to $130 from $82 on Thursday, ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

While acknowledging that Keytruda’s loss of exclusivity in 2028 represents the largest patent cliff in biopharma, BMO said it ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

Merck (MRK) just cleared an important clinical hurdle, reporting strong Phase 3 KEYNOTE B15 results showing that KEYTRUDA ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

Pfizer (PFE) stock is in focus as the firm with Astellas (ALPMF) post a Phase 3 trial win for Padcev cancer drug when used ...

The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...